Spinal fentanyl
ApprovedSmall molecule
Spinal fentanyl is one of 8 small molecule programs targeting Bradycardia. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Bradycardia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Oncology Ltd.
Approved
Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Spinal fentanyl
AAugusta University
Approved
Robinul
Alnylam PharmaceuticalsPreclinical
Corlanor
AmgenPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Infanrix
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bradycardia1 trial
Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia
Unknown status·—·Phase 4·NCT03623256·558 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spinal fentanyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAugusta University